|
Characteristic
|
Total (N = 44)
|
|---|
|
Age, years
| |
|
Median
|
67
|
|
Range
|
51–84
|
|
Gleason score available, n (%)
|
39 (89)
|
|
≤7
|
15 (38)
|
|
>7
|
24 (62)
|
|
PSA level at baseline, ng/mL
| |
|
Median
|
22.2
|
|
Range
|
0.2–746
|
|
Extent of disease, n (%)
| |
|
Local relapse
|
6 (14)
|
|
Locoregional
|
1 (2)
|
|
Metastases total
|
36 (84)
|
|
Peritoneum
|
1 (2)
|
|
Pelvis
|
1 (2)
|
|
Bladder
|
1 (2)
|
|
Lung
|
3 (7)
|
|
Liver
|
1 (2)
|
|
Lymph nodes
|
26 (59)
|
|
Bone
|
28 (64)
|
|
ECOG, n (%)
| |
|
0
|
43 (98)
|
|
1
|
1 (2)
|
|
Time since diagnosis, weeks
| |
|
Mean
|
280.4
|
|
SD
|
228.15
|
|
Previous therapy, n (%)
| |
|
Prostatectomy
|
23 (52)
|
|
Radiotherapy
|
28 (64)
|
|
Hormone ablation
|
44 (100)
|
- ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen; SD, standard deviation
